M184I/V substitutions and E138K/M184I/V double substitutions in HIV reverse transcriptase do not significantly affect the antiviral activity of EFdA

HIV pre-exposure prophylaxis for women and infants prevents vaginal and oral HIV transmission in a preclinical model of HIV infection

(2016) Martina Kovarova et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Efficient Inhibition of HIV Replication in the Gastrointestinal and Female Reproductive Tracts of Humanized BLT Mice by EFdA

(2016) Uma Shanmugasundaram et al.   PLoS One

Structural basis of HIV inhibition by translocation-defective RT inhibitor 4′-ethynyl-2-fluoro-2′-deoxyadenosine (EFdA)

(2016) Zhe Li Salie et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Oral Administration of the Nucleoside EFdA (4′-Ethynyl-2-Fluoro-2′-Deoxyadenosine) Provides Rapid Suppression of HIV Viremia in Humanized Mice and Favorable Pharmacokinetic Properties in Mice and the Rhesus Macaque

(2015) Cheryl A. Stoddart et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Deep sequencing analysis of HIV-1 reverse transcriptase at baseline and time of failure in patients receiving rilpivirine in the phase III studies ECHO and THRIVE

(2015) Veerle Van Eygen et al.   JOURNAL OF MEDICAL VIROLOGY

Delayed emergence of HIV-1 variants resistant to 4’-ethynyl-2-fluoro-2’-deoxyadenosine: comparative sequential passage study with lamivudine, tenofovir, emtricitabine and BMS-986001

(2013) Kenji Maeda et al.   ANTIVIRAL THERAPY

Response of Simian Immunodeficiency Virus to the Novel Nucleoside Reverse Transcriptase Inhibitor 4′-Ethynyl-2-Fluoro-2′-DeoxyadenosineIn VitroandIn Vivo

(2012) Michael Murphey-Corb et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Molecular Mechanism of Antagonism between the Y181C and E138K Mutations in HIV-1 Reverse Transcriptase

(2012) H.-T. Xu et al.   JOURNAL OF VIROLOGY

Synergy against drug-resistant HIV-1 with the microbicide antiretrovirals, dapivirine and tenofovir, in combination

(2011) Susan M. Schader et al.   AIDS

Compensation by the E138K Mutation in HIV-1 Reverse Transcriptase for Deficits in Viral Replication Capacity and Enzyme Processivity Associated with the M184I/V Mutations

(2011) H.-T. Xu et al.   JOURNAL OF VIROLOGY

Interaction of Reverse Transcriptase (RT) Mutations Conferring Resistance to Lamivudine and Etravirine: Effects on Fitness and RT Activity of Human Immunodeficiency Virus Type 1

(2011) Z. Hu et al.   JOURNAL OF VIROLOGY

Development of Antiretroviral Drug Resistance

(2011) Mark A. Wainberg et al.   NEW ENGLAND JOURNAL OF MEDICINE

Characterization of the E138K Resistance Mutation in HIV-1 Reverse Transcriptase Conferring Susceptibility to Etravirine in B and Non-B HIV-1 Subtypes

(2010) Eugene L. Asahchop et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Differential impact of the HIV-1 non-nucleoside reverse transcriptase inhibitor mutations K103N and M230L on viral replication and enzyme function

(2010) H.-T. Xu et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

TMC278, a Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI), Active against Wild-Type and NNRTI-Resistant HIV-1

(2009) H. Azijn et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Mechanism of Inhibition of HIV-1 Reverse Transcriptase by 4′-Ethynyl-2-fluoro-2′-deoxyadenosine Triphosphate, a Translocation-defective Reverse Transcriptase Inhibitor

(2009) Eleftherios Michailidis et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

2′-Deoxy-4′-C-ethynyl-2-halo-adenosines active against drug-resistant human immunodeficiency virus type 1 variants

(2008) Atsushi Kawamoto et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY